Cargando…
AFF3 upregulation mediates tamoxifen resistance in breast cancers
BACKGROUND: Although tamoxifen is a highly effective drug for treating estrogen receptor–positive (ER(+)) breast cancer, nearly all patients with metastasis with initially responsive tumors eventually relapse, and die from acquired drug resistance. Unfortunately, few molecular mediators of tamoxifen...
Autores principales: | Shi, Yawei, Zhao, Yang, Zhang, Yunjian, AiErken, NiJiati, Shao, Nan, Ye, Runyi, Lin, Ying, Wang, Shenming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192118/ https://www.ncbi.nlm.nih.gov/pubmed/30326937 http://dx.doi.org/10.1186/s13046-018-0928-7 |
Ejemplares similares
-
Tripartite motif-containing 3 (TRIM3) enhances ER signaling and confers tamoxifen resistance in breast cancer
por: Ye, Runyi, et al.
Publicado: (2021) -
High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients
por: AiErken, NiJiati, et al.
Publicado: (2017) -
Combining Organoid Models with Next-Generation Sequencing to Reveal Tumor Heterogeneity and Predict Therapeutic Response in Breast Cancer
por: Liu, Yuhong, et al.
Publicado: (2022) -
Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in patients with breast cancer: a meta-analysis
por: Zhou, Yu, et al.
Publicado: (2017) -
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
por: Shao, Nan, et al.
Publicado: (2019)